Deep Insight Research
Investment Thesis
Deep Insight is the first dedicated venture fund in Israel focused solely on deep tech, investing across every stage and every scientific or engineering discipline rather than a single vertical. The firm's public framing — "we can't solve problems by using the same kind of thinking we used when we created them" (their homepage's Einstein epigraph) — signals a thesis built around fundamental scientific and engineering breakthroughs rather than software iteration. They back Israeli-origin founders translating deep technological innovation (physics, materials science, biology, robotics) into solutions for complex, world-scale challenges, and they position themselves as a specialist counterpart to Israel's much larger generalist VC ecosystem.
Sector Focus
The firm states its focus explicitly as "Across All Sectors" within deep tech:
- Semiconductors and photonics
- Bio convergence (biotech interfacing with hardware/software)
- Future robotics
- Advanced materials
- Quantum technologies
- "And other cool stuff" — a deliberately open-ended catch-all for frontier science
In practice, the realized portfolio clusters into four groups: medtech/biotech hardware (Rapid, Bionaut, MediWound, Alpha Tau Medical, Biond Biologics, Averna Therapeutics, Scala Biodesign), semiconductors/photonics/space computing (TriEye, Dust Photonics, Ramon.Space), defense and aerospace (SpearUAV, Regulus), and industrial/materials/agtech (Magnus Metal, Addionics, GreenEye, Particle).
Stage Focus
Deep Insight brands itself explicitly as "STAGE AGNOSTIC" — the first Israeli fund dedicated to deep tech "in all stages." Third-party fund databases (VentureCapitalArchive) describe Fund I, established 2021, as check sizes of $250K–$5M, consistent with seed-through-growth participation observed in the portfolio (seed rounds alongside a $39M Series B in Addionics).
Check Size
Reported range (third-party sourced, moderate confidence): $250K–$5M per investment. Observed check sizes in named rounds span from smaller seed tickets up to co-leading a $39M Series B (Addionics) and leading a $20M growth round (Greeneye Technology).
Lead Tendency
Mixed. Deep Insight led Greeneye Technology's $20M round (April 2024) and co-led Addionics' $39M Series B alongside GM Ventures (July 2024), but participated as a non-lead investor in Scala Biodesign's $16M Series A led by Grove Ventures (March 2026). This points to a firm that leads when it originates or has conviction on a deal but is comfortable following strong co-investors like Grove Ventures and TLV Partners in syndicates.
Recent Activity
Confirmed activity in the past two years:
- March 2026: Participated in Scala Biodesign's $16M Series A (computational protein design), alongside Grove Ventures (lead), TLV Partners, and the Israel Innovation Authority.
- July 2024: Co-led (with GM Ventures) Addionics' $39M Series B for 3D-structured EV battery technology.
- April 2024: Led Greeneye Technology's $20M round to scale AI-enabled precision spraying operations in the US.
Third-party trackers (CB Insights, PitchBook) list roughly 11 disclosed investments to date, with Scala Biodesign as the most recent.
Portfolio Highlights
Sixteen companies are listed directly on the firm's site: TriEye (SWIR sensing for AVs), Rapid Medical (neurovascular devices), Ramon.Space (space-grade computing), Aviv Scientific (brain health clinics using AI/data science), Biond Biologics (immunotherapy/intracellular drug delivery), Addionics (3D battery architecture), Bionaut Labs (micro-robots for CNS disorders), MediWound (biopharma tissue repair, Nasdaq: MDWD), Alpha Tau Medical (alpha-radiation cancer therapy, Nasdaq: DRTS), Magnus Metal (digital metal casting), Averna Therapeutics (gene therapy), GreenEye (AI precision agriculture), Particle (acceleration architectures for industry), SpearUAV (loitering munitions), Dust Photonics (silicon photonics for optical connectivity), and Regulus (counter-drone defense systems). Scala Biodesign (AI-driven protein design) is a newer addition confirmed via its March 2026 funding announcement. Alpha Tau Medical and MediWound are both publicly traded, making them the firm's clearest exit-adjacent liquidity markers to date.
Team
- Eyal Kishon, Managing Partner — three decades in venture capital; Ph.D. in Computer Science & Robotics from NYU.
- Barak Ben-Eliezer, Managing Partner — 15+ years in deep tech investing; former commander of Talpiot, the IDF's elite technology unit.
- Ido Kilberg, Principal — 4+ years in management consulting at EY; background in market research and operations.
- Noa Yehoshua, Value Creation & Ops Lead — 3+ years in VC operations, marketing, and ecosystem relations; background in psychology and diplomacy.
- Nadav Cohen, Venture Partner — 30+ years of deep tech execution and management; Head of Science and Technology at DDR&D (Israel's Directorate of Defense R&D), currently on sabbatical from that role.
Decision Process
With two Managing Partners (Kishon and Ben-Eliezer) plus a Principal and a Venture Partner contributing technical diligence, the firm operates as a partnership rather than a solo-GP structure. No public detail on formal investment committee mechanics.
Founder Preferences
The portfolio consistently favors founders with deep technical/scientific credentials solving hard engineering or scientific problems — protein engineering PhDs, ex-military technologists (SpearUAV, Regulus), and academic spinouts (Scala Biodesign traces to the Weizmann Institute) — over generalist or purely commercial founding teams.
Geographic Focus
Israel-exclusive by explicit positioning: "In Israel there are more Deep Tech opportunities per capita than anywhere else in the world," and "1st dedicated fund in Israel for all Deep Tech opportunities." All identified portfolio companies are Israeli-founded, several (TriEye, Ramon.Space, Bionaut, Regulus) with commercial or operational reach into the US and Europe.
Office
Herzliya Hills, 3 Arik Einstein St., 8th Floor, Herzliya, Israel — a location shared by many Israeli tech and VC firms in the Herzliya Pituach tech corridor.